Second-generation tyrosine kinase inhibitors for chronic myeloid leukemia

1 Views
administrator
administrator
07/08/23

At the 20th Congress of the European Hematology Association (EHA), Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the role of second-generation tyrosine kinase inhibitors (TKIs), nilotinib and dasatinib, in the management of patients with chronic myeloid leukemia (CML).

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next